中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 41 Issue 3
Mar.  2025
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(3): 556-560

Application of Model for End-Stage Liver Disease score in end-stage liver disease

DOI: 10.12449/JCH250325
  • 1.

    Department of Gastroenterology，Affiliated Hospital of Inner Mongolia University for The Nationalities，Tongliao，Inner Mongolia 028000，China

  • 2.

    Department of Gastroenterology，The First Affiliated Hospital of China Medical University，Shenyang 110001，China

Research funding:

National Natural Science Foundation of China Young Scientist Fund (8170030364)

More Information
  • Corresponding author: SU Ya， suyajiayou2020@126.com （ORCID： 0009-0002-9193-3254）
  • Received Date: 2024-07-02
  • Accepted Date: 2024-08-15
  • Published Date: 2025-03-25
    Abstract
  • The Model for End-Stage Liver Disease （MELD） score is currently used to prioritize liver allocation for cirrhotic patients awaiting liver transplantation in the world. With the application of MELD score in transplantation for patients with severe conditions， several models have been proposed to refine and improve MELD score. MELD score has also been used for the management of non-transplantation patients with chronic liver disease. This article briefly reviews the background of these models and believes that the original intention of MELD is to determine the priority of organ allocation for liver transplantation. The expanded application of MELD score beyond liver transplantation assessment should be performed with reference to clinical practice， and different MELD models should be selected rationally based on individual conditions， in order to help patients achieve optimal prognosis assessment， intervention measures， and benefits.

     

    • FullText(HTML)
    • References(43)
  • [1]
    SHARMA P, SCHAUBEL DE, SIMA CS, et al. Re-weighting the model for end-stage liver disease score components[J]. Gastroenterology, 2008, 135( 5): 1575- 1581. DOI: 10.1053/j.gastro.2008.08.004.
    [2]
    LEISE MD, KIM W RAY, KREMERS WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation[J]. Gastroenterology, 2011, 140( 7): 1952- 1960. DOI: 10.1053/j.gastro.2011.02.017.
    [3]
    BIGGINS SW, RODRIGUEZ HJ, BACCHETTI P, et al. Serum sodium predicts mortality in patients listed for liver transplantation[J]. Hepatology, 2005, 41( 1): 32- 39. DOI: 10.1002/hep.20517.
    [4]
    KIM W RAY, MANNALITHARA A, HEIMBACH JK, et al. MELD 3.0: The model for end-stage liver disease updated for the modern era[J]. Gastroenterology, 2021, 161( 6): 1887- 1895. e 4. DOI: 10.1053/j.gastro.2021.08.050.
    [5]
    STARLINGER P, AHN JC, MULLAN A, et al. The addition of C-reactive protein and von willebrand factor to model for end-stage liver disease-sodium improves prediction of waitlist mortality[J]. Hepatology, 2021, 74( 3): 1533- 1545. DOI: 10.1002/hep.31838.
    [6]
    ASRANI SK, JENNINGS LW, KIM WR, et al. MELD-GRAIL-Na: Glomerular filtration rate and mortality on liver-transplant waiting list[J]. Hepatology, 2020, 71( 5): 1766- 1774. DOI: 10.1002/hep.30932.
    [7]
    GARBER K. Controversial allocation rules for liver transplants[J]. Nat Med, 2002, 8( 2): 97. DOI: 10.1038/nm0202-97a.
    [8]
    MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31( 4): 864- 871. DOI: 10.1053/he.2000.5852.
    [9]
    KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33( 2): 464- 470. DOI: 10.1053/jhep.2001.22172.
    [10]
    WIESNER R, EDWARDS E, FREEMAN R, et al. Model for end-stage liver disease(MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124( 1): 91- 96. DOI: 10.1053/gast.2003.50016.
    [11]
    OLTHOFF KM, BROWN RS Jr, DELMONICO FL, et al. Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA[J]. Liver Transpl, 2004, 10(10 Suppl 2): A6- 22. DOI: 10.1002/lt.20247.
    [12]
    WIESNER R, LAKE JR, FREEMAN RB, et al. Model for end-stage liver disease(MELD) exception guidelines[J]. Liver Transpl, 2006, 12(12 Suppl 3): S85- S87. DOI: 10.1002/lt.20961.
    [13]
    LIM YS, LARSON TS, BENSON JT, et al. Serum sodium, renal function, and survival of patients with end-stage liver disease[J]. J Hepatol, 2010, 52( 4): 523- 528. DOI: 10.1016/j.jhep.2010.01.009.
    [14]
    ASRANI SK, KAMATH PS. Model for end-stage liver disease score and MELD exceptions: 15 years later[J]. Hepatol Int, 2015, 9( 3): 346- 354. DOI: 10.1007/s12072-015-9631-3.
    [15]
    QUANTE M, BENCKERT C, THELEN A, et al. Experience since MELD implementation: How does the new system deliver?[J]. Int J Hepatol, 2012, 2012: 264015. DOI: 10.1155/2012/264015.
    [16]
    D’AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44( 1): 217- 231. DOI: 10.1016/j.jhep.2005.10.013.
    [17]
    TEH SH, NAGORNEY DM, STEVENS SR, et al. Risk factors for mortality after surgery in patients with cirrhosis[J]. Gastroenterology, 2007, 132( 4): 1261- 1269. DOI: 10.1053/j.gastro.2007.01.040.
    [18]
    KAMATH PS, KIM W RAY, GROUP ALDS. The model for end-stage liver disease(MELD)[J]. Hepatology, 2007, 45( 3): 797- 805. DOI: 10.1002/hep.21563.
    [19]
    KREMERS WK, VAN IJPEREN M, KIM WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients[J]. Hepatology, 2004, 39( 3): 764- 769. DOI: 10.1002/hep.20083.
    [20]
    KIM MS, KATO TS, FARR M, et al. Hepatic dysfunction in ambulatory patients with heart failure: Application of the MELD scoring system for outcome prediction[J]. J Am Coll Cardiol, 2013, 61( 22): 2253- 2261. DOI: 10.1016/j.jacc.2012.12.056.
    [21]
    MITRA A, MYERS L, AHN J. Assessing the severity and prognosis of alcoholic hepatitis[J]. Clin Liver Dis, 2021, 25( 3): 585- 593. DOI: 10.1016/j.cld.2021.03.004.
    [22]
    JOPHLIN LL, SINGAL AK, BATALLER R, et al. ACG clinical guideline: Alcohol-associated liver disease[J]. Am J Gastroenterol, 2024, 119( 1): 30- 54. DOI: 10.14309/ajg.0000000000002572.
    [23]
    FORREST EH, ATKINSON SR, RICHARDSON P, et al. Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis[J]. J Hepatol, 2018, 68( 3): 511- 518. DOI: 10.1016/j.jhep.2017.11.017.
    [24]
    MORALES-ARRÁEZ D, VENTURA-COTS M, ALTAMIRANO J, et al. The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: A global study[J]. Am J Gastroenterol, 2022, 117( 2): 301- 310. DOI: 10.14309/ajg.0000000000001596.
    [25]
    FINK MA, ANGUS PW, GOW PJ, et al. Liver transplant recipient selection: MELD vs. clinical judgment[J]. Liver Transpl, 2005, 11( 6): 621- 626. DOI: 10.1002/lt.20428.
    [26]
    HEUMAN DM, ABOU-ASSI SG, HABIB A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death[J]. Hepatology, 2004, 40( 4): 802- 810. DOI: 10.1002/hep.20405.
    [27]
    BIGGINS SW, KIM W RAY, TERRAULT NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130( 6): 1652- 1660. DOI: 10.1053/j.gastro.2006.02.010.
    [28]
    KALRA A, WEDD JP, BIGGINS SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more[J]. Curr Opin Organ Transplant, 2016, 21( 2): 120- 126. DOI: 10.1097/MOT.0000000000000281.
    [29]
    SHARMA P, SCHAUBEL DE, GOODRICH NP, et al. Serum sodium and survival benefit of liver transplantation[J]. Liver Transpl, 2015, 21( 3): 308- 313. DOI: 10.1002/lt.24063.
    [30]
    KIM JJ, KIM JH, KOO JK, et al. The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites[J]. Clin Mol Hepatol, 2014, 20( 1): 47- 55. DOI: 10.3350/cmh.2014.20.1.47.
    [31]
    CHETWOOD JD, WELLS MG, TSOUTSMAN T, et al. MELD-GRAIL and MELD-GRAIL-Na are not superior to MELD or MELD-Na in predicting liver transplant waiting list mortality at a single-center level[J]. Transplant Direct, 2022, 8( 7): e1346. DOI: 10.1097/TXD.0000000000001346.
    [32]
    THABUT D, MASSARD J, GANGLOFF A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J]. Hepatology, 2007, 46( 6): 1872- 1882. DOI: 10.1002/hep.21920.
    [33]
    CAZZANIGA M, DIONIGI E, GOBBO G, et al. The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome[J]. J Hepatol, 2009, 51( 3): 475- 482. DOI: 10.1016/j.jhep.2009.04.017.
    [34]
    BLAYA D, RUBIO-TOMÁS T, RODRIGO-TORRES D, et al. Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis[J]. Hepatol Int, 2021, 15( 4): 1006- 1017. DOI: 10.1007/s12072-021-10165-y.
    [35]
    WOOD NL, VANDERWERKEN D, SEGEV DL, et al. Correcting the sex disparity in MELD-Na[J]. Am J Transplant, 2021, 21( 10): 3296- 3304. DOI: 10.1111/ajt.16731.
    [36]
    LOCKE JE, SHELTON BA, OLTHOFF KM, et al. Quantifying sex-based disparities in liver allocation[J]. JAMA Surg, 2020, 155( 7): e201129. DOI: 10.1001/jamasurg.2020.1129.
    [37]
    European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
    [38]
    KIM W RAY, MANNALITHARA A, KWO PY, et al. Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40[J]. Hepatology, 2023, 77( 3): 851- 861. DOI: 10.1002/hep.32770.
    [39]
    SINGEAP AM, MINEA H, PETREA O, et al. Real-world utilization of corticosteroids in severe alcoholic hepatitis: Eligibility, response, and outcomes[J]. Medicina(Kaunas), 2024, 60( 2): 311. DOI: 10.3390/medicina60020311.
    [40]
    KWONG AJ, EBEL NH, KIM WR, et al. OPTN/SRTR 2020 annual data report: Liver[J]. Am J Transplant, 2022, 22( Suppl 2): 204- 309. DOI: 10.1111/ajt.16978.
    [41]
    MAZUMDER NR, FONTANA RJ. MELD 3.0 in advanced chronic liver disease[J]. Annu Rev Med, 2024, 75: 233- 245. DOI: 10.1146/annurev-med-051322-122539.
    [42]
    PAPASTERGIOU V, TSOCHATZIS EA, PIERI G, et al. Nine scoring models for short-term mortality in alcoholic hepatitis: Cross-validation in a biopsy-proven cohort[J]. Aliment Pharmacol Ther, 2014, 39( 7): 721- 732. DOI: 10.1111/apt.12654.
    [43]
    LA DÍAZ, FUENTES-LÓPEZ E, AYARES G, et al. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis[J]. JHEP Rep, 2023, 5( 8): 100727. DOI: 10.1016/j.jhepr.2023.100727.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (645) PDF downloads(26) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3692]YesterdayPV[7162]TodayIP[1943]TodayPV[4393]Online[424]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return